Compare STRA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | ANIP |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1996 | 1999 |
| Metric | STRA | ANIP |
|---|---|---|
| Price | $80.32 | $74.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $96.50 | ★ $107.33 |
| AVG Volume (30 Days) | 302.2K | ★ 338.3K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 15.85 | ★ 419.23 |
| EPS | ★ 5.41 | 3.32 |
| Revenue | ★ $997,137,000.00 | $206,547,000.00 |
| Revenue This Year | $4.71 | $19.88 |
| Revenue Next Year | $2.48 | $15.77 |
| P/E Ratio | ★ $14.85 | $22.32 |
| Revenue Growth | ★ 57.23 | 2.47 |
| 52 Week Low | $72.17 | $56.71 |
| 52 Week High | $92.98 | $99.50 |
| Indicator | STRA | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 44.96 |
| Support Level | $79.98 | $62.89 |
| Resistance Level | $84.71 | $85.12 |
| Average True Range (ATR) | 3.18 | 2.87 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.02 | 50.45 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.